Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC(50)] = 354 nM) and in human fetal hepatocytes infected with genotyp...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Perni, Robert B., Almquist, Susan J., Byrn, Randal A., Chandorkar, Gurudatt, Chaturvedi, Pravin R., Courtney, Lawrence F., Decker, Caroline J., Dinehart, Kirk, Gates, Cynthia A., Harbeson, Scott L., Heiser, Angela, Kalkeri, Gururaj, Kolaczkowski, Elaine, Lin, Kai, Luong, Yu-Ping, Rao, B. Govinda, Taylor, William P., Thomson, John A., Tung, Roger D., Wei, Yunyi, Kwong, Ann D., Lin, Chao
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2006
Soggetti:
Antiviral Agents
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1426435/
https://ncbi.nlm.nih.gov/pubmed/16495249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.50.3.899-909.2006
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi